Acquisitions

M&A activity

16 stories

In the last 7 days, Acquisitions tracked 1 story — 100% neutral sentiment, averaging 5/10 impact.

Stories appear on this page because our classification stage assigned them this category as their primary topic — each story receives exactly one category per niche, chosen from a fixed list, so a story that touches both a funding round and a product launch in the same week sorts into whichever category best matches its dominant subject, not both. This keeps each category page focused on one beat rather than a blend of unrelated developments, and applies the same source-verification standard used across every story on this site. Sentiment measures the directional read of each development for this category specifically, not the tone of the reporting, and impact weights how consequential a development is — regulatory, financial, or operational — rather than how widely it was syndicated across outlets.

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

Bullish 7

H.B. Fuller's £659M AMS Deal Powers 35% Premium into Medical Adhesives Market

H.B. Fuller's $870 million acquisition of Advanced Medical Solutions signals a major vote of confidence in advanced wound care and surgical sealants. For healthcare providers, this deal promises innovative products for chronic wounds and surgical closures, potentially improving patient outcomes and reducing costs.

Verified by 2 sources
Bullish 7

Wellgistics Health Targets CNS Market with $105M Neuritek Acquisition Bid

Wellgistics Health Inc. has signed a $105 million Letter of Intent to evaluate the acquisition of Neuritek Therapeutics, a biotech firm specializing in neurological and psychiatric treatments. The deal marks a significant strategic expansion for Wellgistics into the high-growth central nervous system (CNS) therapeutic sector.

Verified by 2 sources

Source: jamaicantimes.com · californiatelegraph.com

Bullish 8

Novartis Bolsters Oncology Pipeline with $3B Acquisition of SNV4818

Novartis AG has entered into a definitive agreement to acquire an experimental breast cancer drug candidate, SNV4818, from Delaware-based Synnovation Therapeutics for up to $3 billion. This strategic acquisition aims to strengthen Novartis's leadership in the oncology market as it continues its pivot toward high-value innovative medicines.

Verified by 3 sources

Source: Seeking Alpha · Bloomberg

Very Bullish 6

Aster DM Healthcare Secures Shareholder Approval for Landmark QCIL Merger

Aster DM Healthcare has cleared a critical regulatory hurdle as shareholders and creditors overwhelmingly approved its merger with Quality Care India Limited (QCIL). This consolidation, backed by Blackstone, is set to create one of India's largest private healthcare networks with a significantly expanded bed capacity and geographic footprint.

Verified by 2 sources

Source: thehindubusinessline.com · nepalnational.com

Bullish 6

Lifeward and Oramed Secure Shareholder Approval for Strategic Biomedical Merger

Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.

Verified by 2 sources

Source: finanznachrichten.de · manilatimes.net

Neutral 7

Universal Health Services to Acquire Talkspace for $835 Million

Universal Health Services (UHS) has reached a definitive agreement to acquire virtual mental health provider Talkspace for $835 million. The deal merges one of the nation's largest inpatient behavioral health networks with a leading digital therapy platform, signaling a major shift toward hybrid care models.

Verified by 2 sources

Source: STAT News · Endpoints News

Bullish 7

Hims & Hers Acquires Eucalyptus for $1.6B in Global Telehealth Consolidation

US telehealth leader Hims & Hers has finalized a $1.6 billion acquisition of Australian digital health startup Eucalyptus, marking a major expansion into the Asia-Pacific market. The deal, driven by the explosive growth of GLP-1 weight-loss treatments, creates over 100 employee millionaires and solidifies Hims & Hers' position as a global powerhouse in direct-to-consumer healthcare.

Verified by 2 sources

About Healthcare Acquisitions coverage

According to our own tracking database, this category has accumulated 16 acquisitions stories since coverage began. This page aggregates the latest acquisitions stories within our healthcare coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track m&a activity and surface the angles a domain expert would actually read.

Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the healthcare beat.

Stories only surface on this page once the classifier scores them at a minimum 35 percent relevance to the category. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

SignalWhat it tells you
Verified by N sourcesConfidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated.
Impact score (1-10)Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on.
SentimentFive-tier classification (very bullish through very bearish) trained on labeled healthcare-specific corpora.
Time stampRecency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed.